352 related articles for article (PubMed ID: 36265805)
1. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
Zhu Y; Hu Y; Liu N; Chong H; He Y
Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.
Zhu Y; Dong X; Liu N; Wu T; Chong H; Lei X; Ren L; Wang J; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):1819-1827. PubMed ID: 35786417
[TBL] [Abstract][Full Text] [Related]
3. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
[TBL] [Abstract][Full Text] [Related]
4. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
5. Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
Hu Y; Zhu Y; Yu Y; Liu N; Ju X; Ding Q; He Y
Antiviral Res; 2023 Apr; 212():105571. PubMed ID: 36868315
[TBL] [Abstract][Full Text] [Related]
6. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
[TBL] [Abstract][Full Text] [Related]
9. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
[TBL] [Abstract][Full Text] [Related]
10. The impact of S2 mutations on Omicron SARS-CoV-2 cell surface expression and fusogenicity.
Escalera A; Laporte M; Turner S; Karakus U; Gonzalez-Reiche AS; van de Guchte A; Farrugia K; Khalil Z; van Bakel H; Smith D; García-Sastre A; Aydillo T
Emerg Microbes Infect; 2024 Dec; 13(1):2297553. PubMed ID: 38112266
[TBL] [Abstract][Full Text] [Related]
11. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
Xia S; Wang L; Zhu Y; Lu L; Jiang S
Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
14. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.
Zhou Y; Zhi H; Teng Y
J Med Virol; 2023 Jan; 95(1):e28138. PubMed ID: 36097349
[TBL] [Abstract][Full Text] [Related]
15. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
16. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
[TBL] [Abstract][Full Text] [Related]
17. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Iketani S; Liu L; Guo Y; Liu L; Chan JF; Huang Y; Wang M; Luo Y; Yu J; Chu H; Chik KK; Yuen TT; Yin MT; Sobieszczyk ME; Huang Y; Yuen KY; Wang HH; Sheng Z; Ho DD
Nature; 2022 Apr; 604(7906):553-556. PubMed ID: 35240676
[TBL] [Abstract][Full Text] [Related]
18. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
Hu B; Chan JF; Liu H; Liu Y; Chai Y; Shi J; Shuai H; Hou Y; Huang X; Yuen TT; Yoon C; Zhu T; Zhang J; Li W; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Yuen KY; Chu H
Emerg Microbes Infect; 2022 Dec; 11(1):2275-2287. PubMed ID: 36039901
[TBL] [Abstract][Full Text] [Related]
19. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
[TBL] [Abstract][Full Text] [Related]
20. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]